ASH 2021 | Future directions in chronic phase CML treatment
Gabriela Hobbs
• 11 Dec 2021
In this video, Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, summarizes future therapeutic options for patients with chronic phase chronic myeloid leukemia (CML), drawing focus on novel agents that offer promising results for patients. Dr Hobbs highlights the recent approval of asciminib, a novel tyrosine kinase inhibitor (TKI), and emphasizes the importance of trying to help patients achieve a deep remission that allows them to eventually discontinue TKI therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
